GO:0004578 chitobiosyldiphosphodolichol beta-mannosyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004578 describes the enzymatic activity that adds the first mannose to the growing N-glycan precursor on dolichol-linked chitobiose, forming Man-beta-1,4-GlcNAc-GlcNAc-PP-dolichol [1,2].
• This activity is essential for protein N-glycosylation and is conserved from yeast to humans, where the orthologous enzyme is encoded by ALG1 [2,6].
• Deficiency of this enzyme causes congenital disorder of glycosylation type Ik (CDG-Ik), a severe multisystem disease.
• The enzyme uses GDP-mannose as the mannose donor and requires a dolichol-pyrophosphate-chitobiose acceptor.
• The dolichol recognition sequence is not strictly required for catalytic activity when a soluble acceptor analog is used.
• ALG1 and related genes have been associated with schizophrenia in genetic studies, highlighting broader neurological relevance.
Description
Chitobiosyldiphosphodolichol beta-mannosyltransferase activity (GO:0004578) is a molecular function that catalyzes the transfer of a beta-D-mannose residue from GDP-alpha-D-mannose to an N,N'-diacetylchitobiosyl-diphospho-dolichol acceptor, producing a beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-dolichol intermediate [1,2]. This reaction is the first mannosylation step in the assembly of the dolichol-linked oligosaccharide precursor required for protein N-glycosylation [2,4]. The enzyme responsible is known as Alg1 in yeast and ALG1 in humans, and its activity is essential for the subsequent addition of further mannose and glucose residues that ultimately form the Glc3Man9GlcNAc2 precursor [2,6]. Researchers study GO:0004578 because defects in this activity disrupt N-glycosylation and lead to congenital disorders of glycosylation, particularly CDG-Ik, which presents with severe neurological and systemic symptoms. The enzyme has also been implicated in broader cellular processes, including cell wall integrity in fungi and neurological traits in humans [1,5]. Understanding its mechanism, regulation, and substrate specificity is therefore critical for both basic glycobiology and therapeutic development. The activity is highly conserved across eukaryotes, and its study has been facilitated by recombinant expression systems, enzymatic assays, and structural analyses [2,6,7]. This article provides a comprehensive overview of the gene, its function, associated diseases, and the experimental models used to investigate it.
chitobiosyldiphosphodolichol beta-mannosyltransferase activity At A Glance
| GO ID | GO:0004578 |
|---|---|
| GO term | chitobiosyldiphosphodolichol beta-mannosyltransferase activity |
| Ontology | molecular_function |
| Synonym | GDP-mannose:chitobiosyldiphosphodolichol beta-D-mannosyltransferase activity; GDP-mannose-dolichol diphosphochitobiose mannosyltransferase activity; guanosine diphosphomannose-dolichol diphosphochitobiose mannosyltransferase activity |
| Major function | Transfer of beta-D-mannose from GDP-mannose to chitobiosyl-diphosphodolichol, the first mannosylation step in N-glycan precursor assembly [1,2] |
| Substrates | GDP-alpha-D-mannose and N,N'-diacetylchitobiosyl-diphospho-dolichol |
| Products | beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-dolichol, GDP, and H+ |
| Cellular location | Endoplasmic reticulum membrane |
| Enzyme class | Glycosyltransferase (mannosyltransferase) |
What Is GO:0004578?
GO:0004578 is defined as the catalysis of the reaction: an N,N'-diacetylchitobiosyl-diphospho-di-trans,poly-cis-dolichol + GDP-alpha-D-mannose = a beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + GDP + H+. In simpler terms, it is the enzyme activity that attaches the first mannose sugar to a lipid-linked chitobiose molecule, a key step in building the N-glycan precursor [1,2].
Why Is chitobiosyldiphosphodolichol beta-mannosyltransferase activity Important in Cell Biology?
GO:0004578 is a critical enzymatic activity in the N-glycosylation pathway, as it initiates the mannose extension of the dolichol-linked oligosaccharide precursor. Without this activity, cells cannot synthesize mature N-glycans, leading to protein misfolding, ER stress, and severe developmental defects. The enzyme is also a target for antifungal drug development because fungal cell wall integrity depends on proper N-glycosylation. In humans, mutations in ALG1 cause CDG-Ik, a devastating disorder with neurological involvement, underscoring the clinical importance of this activity.
• Essential for protein N-glycosylation, affecting cell surface receptors, adhesion molecules, and secreted proteins.
• Deficiency causes congenital disorder of glycosylation type Ik (CDG-Ik), a severe multisystem disease.
• Associated with schizophrenia in genetic association studies, suggesting a role in neurodevelopment.
• Required for fungal cell wall integrity and virulence, making it a potential antifungal target.
• Its activity can be measured quantitatively, enabling high-throughput screening for inhibitors.
• The enzyme is conserved from yeast to humans, facilitating model organism studies [2,6].
• Recombinant forms are used for chemoenzymatic synthesis of N-linked oligosaccharides.
• The dolichol recognition sequence is not essential for catalysis, providing insights into substrate specificity.
Molecular Mechanism of chitobiosyldiphosphodolichol beta-mannosyltransferase activity
Substrate Recognition and Binding
In simple terms: The enzyme grabs the sugar donor and the lipid-linked acceptor to start the reaction.
The enzyme binds GDP-mannose as the mannose donor and the chitobiosyl-diphosphodolichol acceptor. The acceptor consists of two N-acetylglucosamine residues linked to dolichol via a pyrophosphate bridge. The enzyme recognizes the chitobiose moiety and the dolichol chain, although the dolichol recognition sequence is not strictly required for activity when a soluble analog is used.
Catalytic Transfer of Mannose
In simple terms: The enzyme snips off mannose from GDP-mannose and attaches it to the chitobiose lipid.
The catalytic mechanism involves the transfer of beta-D-mannose from GDP-alpha-D-mannose to the 4-position of the terminal N-acetylglucosamine of the acceptor, forming a beta-1,4 linkage [1,2]. This reaction releases GDP and a proton. The enzyme is a beta-mannosyltransferase, and its activity is dependent on divalent cations, although specific cofactor requirements may vary.
Enzyme Structure and Transmembrane Topology
In simple terms: The enzyme is anchored in the ER membrane with its active site facing the cytoplasm.
ALG1 is an integral membrane protein of the endoplasmic reticulum. It contains multiple transmembrane domains, and the catalytic domain faces the cytoplasmic side of the ER, where GDP-mannose is available. The transmembrane domain properties have been analyzed using prokaryotic expression systems, revealing insights into its membrane integration.
Kinetic Properties and Assay Development
In simple terms: Scientists can measure how fast the enzyme works using artificial substrates.
Quantitative studies of yeast Alg1 beta-1,4-mannosyltransferase activity have been performed using fluorescent or radioactive substrates, allowing determination of kinetic parameters such as Km and Vmax. Recombinant, immobilized forms of the enzyme have been developed for chemoenzymatic synthesis of N-linked oligosaccharides, demonstrating its utility as a biocatalyst.
Regulation and Stability
In simple terms: The enzyme's activity can change with environmental conditions like temperature and pH.
In Candida albicans, the activity and stability of alpha- and beta-mannosyltransferases, including the Alg1 ortholog, are influenced by growth temperature and pH, suggesting that environmental factors regulate N-glycosylation. This regulation may be important for adaptation and pathogenesis.
Key Genes Involved in GO:0004578 chitobiosyldiphosphodolichol beta-mannosyltransferase activity
The following genes and proteins are directly involved in or closely associated with chitobiosyldiphosphodolichol beta-mannosyltransferase activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALG1 (human) | Encodes the beta-1,4-mannosyltransferase that catalyzes GO:0004578 | Mutations cause CDG-Ik; associated with schizophrenia [1,8] |
| ALG1 (yeast) | Ortholog of human ALG1; essential for N-glycosylation | Model for enzymatic studies and drug screening |
| ALG2 | Alpha-1,3-mannosyltransferase that acts after Alg1 | Downstream step in N-glycan assembly |
| ALG3 | Alpha-1,3-mannosyltransferase | Further mannose addition in the ER |
| ALG5 | Dolichyl-phosphate beta-glucosyltransferase | Glucose addition to the precursor |
| ALG6 | Alpha-1,3-glucosyltransferase | Glucose addition in the ER |
| ALG8 | Alpha-1,3-glucosyltransferase | Glucose addition in the ER |
| ALG9 | Alpha-1,2-mannosyltransferase | Mannose addition in the ER |
| ALG10 | Alpha-1,2-glucosyltransferase | Final glucose addition in the ER |
| ALG11 | Alpha-1,2-mannosyltransferase | Mannose addition in the ER |
| ALG12 | Alpha-1,6-mannosyltransferase | Mannose addition in the ER |
| ALG13 | UDP-GlcNAc transferase subunit | Part of the oligosaccharyltransferase complex |
| ALG14 | UDP-GlcNAc transferase subunit | Part of the oligosaccharyltransferase complex |
| DPM1 | Dolichol-phosphate mannosyltransferase | Synthesizes dolichol-phosphate-mannose for various mannosylation reactions |
| MPDU1 | Mannose-P-dolichol utilization defect 1 | Required for efficient utilization of dolichol-phosphate-mannose |
| DDOST | Oligosaccharyltransferase subunit | Transfers the completed glycan to proteins |
| RPN1 | Oligosaccharyltransferase subunit | Assists in glycan transfer |
| RPN2 | Oligosaccharyltransferase subunit | Assists in glycan transfer |
How Is chitobiosyldiphosphodolichol beta-mannosyltransferase activity Regulated?
The activity of chitobiosyldiphosphodolichol beta-mannosyltransferase is primarily regulated at the level of gene expression and by the availability of substrates. In yeast, Alg1 expression is induced under conditions of ER stress via the unfolded protein response pathway. Environmental factors such as temperature and pH also affect the stability and activity of the enzyme in Candida albicans. Additionally, the enzyme requires GDP-mannose, which is synthesized in the cytoplasm; thus, fluctuations in GDP-mannose levels can influence activity. No direct allosteric regulation has been reported, but the enzyme is part of a larger glycosylation machinery that is coordinately regulated.
chitobiosyldiphosphodolichol beta-mannosyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ALG1 | CDG-Ik; schizophrenia | Patient-derived fibroblasts; ALG1 knockout HEK293 cells [1,8] |
| ALG1 (yeast) | N-glycosylation defects; cell wall integrity | Saccharomyces cerevisiae alg1 mutants |
| ALG1 (Candida) | Fungal virulence; stress response | Candida albicans knockout strains |
| WDR3 | Schizophrenia (association) | WDR3 knockout neuronal cells |
| MPDU1 | CDG-If; mannose utilization | MPDU1 knockout cell lines |
Congenital Disorder of Glycosylation Type Ik (CDG-Ik)
Mutations in ALG1 cause CDG-Ik, an autosomal recessive disorder characterized by severe neurological impairment, hypotonia, seizures, and developmental delay. The deficiency in beta-mannosyltransferase activity leads to incomplete N-glycan precursors, resulting in hypoglycosylation of proteins. Diagnosis is typically confirmed by transferrin isoelectric focusing and genetic testing. Management is supportive, as no cure exists.
Schizophrenia and Neurological Traits
Genetic association studies have linked polymorphisms in ALG1 and another gene, WD repeat domain 3 (WDR3), with schizophrenia in a Japanese population. Although the mechanism is not fully understood, impaired N-glycosylation may affect synaptic function and neurodevelopment, contributing to psychiatric phenotypes.
Fungal Pathogenesis and Antifungal Targets
In Candida albicans, beta-mannosyltransferase activity is important for cell wall integrity and virulence. The enzyme's stability at high temperature and low pH suggests adaptation to host niches. Inhibitors of this activity could serve as antifungal agents by weakening the fungal cell wall.
From chitobiosyldiphosphodolichol beta-mannosyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of ALG1 loss on N-glycosylation? | ALG1 knockout HEK293 or HeLa cells |
| Does a specific ALG1 mutation cause CDG-Ik? | Patient-derived fibroblasts or knock-in cells expressing mutant ALG1 |
| How does ALG1 overexpression affect glycosylation flux? | ALG1 overexpression in CHO or HEK293 cells |
| What is the subcellular localization of ALG1? | Tagged knock-in of ALG1 with GFP or FLAG in mammalian cells |
| Can we screen for inhibitors of ALG1? | Recombinant yeast Alg1 enzyme assays or high-throughput screening in Candida albicans |
| What is the role of ALG1 in neuronal development? | ALG1 knockout iPSC-derived neurons or mouse models |
How to Study the chitobiosyldiphosphodolichol beta-mannosyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioactive enzyme assay | Mannosyltransferase activity | Kinetic analysis and inhibitor screening |
| Mass spectrometry | N-glycan profiles | Diagnosis of CDG and pathway analysis |
| Western blot | Protein expression and glycosylation status | Validation of knockout or overexpression |
| Immunofluorescence | Subcellular localization | Determining ER localization of ALG1 |
| CRISPR-Cas9 knockout | Loss-of-function phenotypes | Studying N-glycosylation defects |
| Site-directed mutagenesis | Effect of specific mutations | Modeling CDG-Ik variants |
| Recombinant expression | Enzyme production for structural studies | X-ray crystallography or cryo-EM |
| Chemoenzymatic synthesis | Production of defined oligosaccharides | Biocatalysis and drug development |
Enzymatic Activity Assays
The activity of chitobiosyldiphosphodolichol beta-mannosyltransferase can be measured using radioactive GDP-[3H]mannose and a synthetic acceptor, such as phytanyl-pyrophosphoryl-alpha-N,N'-diacetylchitobioside. The product is extracted and quantified by scintillation counting or HPLC [2,3]. This method is suitable for kinetic studies and inhibitor screening.
Recombinant Protein Expression and Purification
Recombinant ALG1 can be expressed in E. coli or yeast and purified for structural and biochemical studies. Prokaryotic expression of human ALG1 has been used to analyze transmembrane domain properties. Immobilized recombinant beta-1,4-mannosyltransferase has been developed for chemoenzymatic synthesis.
Glycan Analysis by Mass Spectrometry
Changes in N-glycan structures due to altered ALG1 activity can be assessed by mass spectrometry of released glycans from cell lysates or secreted proteins. This method provides a global view of glycosylation defects.
CRISPR-Cas9 Genome Editing
Knockout of ALG1 using CRISPR-Cas9 allows functional studies in cell lines. Point mutations can be introduced to model CDG-Ik patient variants. Knock-in of tagged ALG1 enables localization and interaction studies. Overexpression models help investigate gain-of-function effects [1,8].
How CRISPR Can Be Used to Study GO:0004578 chitobiosyldiphosphodolichol beta-mannosyltransferase activity
Knockout
CRISPR-Cas9 knockout of ALG1 in human cell lines (e.g., HEK293, HeLa) results in loss of beta-mannosyltransferase activity, leading to truncated N-glycans and ER stress. These models are valuable for studying CDG-Ik pathophysiology and for testing therapeutic strategies [1,8].
Point Mutation
Introducing patient-specific point mutations (e.g., missense mutations in ALG1) via CRISPR-Cas9 homology-directed repair allows precise modeling of CDG-Ik. These cells can be used to assess the impact of mutations on enzyme activity, stability, and glycosylation.
Knock-in
Knock-in of a fluorescent or affinity tag (e.g., GFP, FLAG) at the endogenous ALG1 locus enables real-time imaging and proteomic analysis of the enzyme. This approach helps determine subcellular localization and interacting partners.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of ALG1 can increase enzyme levels, potentially enhancing N-glycosylation capacity. This is useful for biotechnological applications, such as improving recombinant protein production.
How EDITGENE Supports chitobiosyldiphosphodolichol beta-mannosyltransferase activity Research
Researchers studying chitobiosyldiphosphodolichol beta-mannosyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in glycosylation disorders or neurological traits. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutation and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for chitobiosyldiphosphodolichol beta-mannosyltransferase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| ALG1L2 Knockout HEK293 Cell Line | EDJ-KQ12331 | Human | 644974 | Details Get a Quote |
| ALG1L2 Knockout HeLa Cell Line | EDJ-KQ60578 | Human | 644974 | Details Get a Quote |
| ALG1L2 Knockout A-549 Cell Line | EDJ-KQ69047 | Human | 644974 | Details Get a Quote |
| ALG1L2 Knockout HCT 116 Cell Line | EDJ-KQ77402 | Human | 644974 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
Frequently Asked Questions About chitobiosyldiphosphodolichol beta-mannosyltransferase activity
What is chitobiosyldiphosphodolichol beta-mannosyltransferase activity?
It is the enzymatic activity (GO:0004578) that transfers a beta-D-mannose from GDP-mannose to chitobiosyl-diphosphodolichol, the first mannosylation step in N-glycan precursor assembly [1,2].
What genes are involved in chitobiosyldiphosphodolichol beta-mannosyltransferase activity?
The primary gene is ALG1 in humans and yeast, which encodes the beta-1,4-mannosyltransferase. Other genes in the pathway include ALG2, ALG3, and DPM1 [2,4].
What diseases are associated with GO:0004578?
Deficiency causes congenital disorder of glycosylation type Ik (CDG-Ik). Genetic variants have also been associated with schizophrenia [1,8].
How is chitobiosyldiphosphodolichol beta-mannosyltransferase activity measured?
It is typically measured using radioactive GDP-mannose and a synthetic acceptor, followed by product quantification via scintillation counting or HPLC [2,3].
What is the role of ALG1 in N-glycosylation?
ALG1 adds the first mannose to the dolichol-linked chitobiose, forming Man-beta-1,4-GlcNAc-GlcNAc-PP-dolichol, which is further elongated to the full N-glycan precursor.
Is chitobiosyldiphosphodolichol beta-mannosyltransferase activity conserved?
Yes, the enzyme is conserved from yeast to humans, with orthologs in many eukaryotes [2,6].
What is CDG-Ik?
CDG-Ik is a congenital disorder of glycosylation caused by mutations in ALG1, leading to severe neurological and developmental symptoms.
Can CRISPR be used to study GO:0004578?
Yes, CRISPR-Cas9 knockout, point mutation, and knock-in models of ALG1 are powerful tools to study the function and dysfunction of this activity [1,8].
What are the substrates of chitobiosyldiphosphodolichol beta-mannosyltransferase?
The substrates are GDP-alpha-D-mannose and N,N'-diacetylchitobiosyl-diphospho-dolichol.
Where is the enzyme located in the cell?
It is an integral membrane protein of the endoplasmic reticulum, with its active site facing the cytoplasm.
Conclusion
Chitobiosyldiphosphodolichol beta-mannosyltransferase activity (GO:0004578) is a fundamental enzymatic step in protein N-glycosylation, with critical roles in human health and disease. Its deficiency causes CDG-Ik, and genetic variants have been linked to schizophrenia. The enzyme is also a potential antifungal target. Advances in CRISPR genome editing and enzymatic assays continue to illuminate its mechanism and regulation, offering opportunities for therapeutic intervention. EDITGENE's comprehensive services support researchers in modeling this activity and related pathways.
References
- 1. Kobayashi M et al.. 2018. Association studies of WD repeat domain 3 and chitobiosyldiphosphodolichol beta-mannosyltransferase genes with schizophrenia in a Japanese population.. PLoS One 13(1):e0190991 PMID: 29309433
- 2. Li ST et al.. 2017. Quantitative study of yeast Alg1 beta-1, 4 mannosyltransferase activity, a key enzyme involved in protein N-glycosylation.. Biochim Biophys Acta Gen Subj 1861(1 Pt A):2934-2941 PMID: 27670784
- 3. Revers L et al.. 1994. The potential dolichol recognition sequence of beta-1,4-mannosyltransferase is not required for enzymic activity using phytanyl-pyrophosphoryl-alpha-N,N'- diacetylchitobioside as acceptor.. Biochem J 299 ( Pt 1)(Pt 1):23-7 PMID: 8166646
- 4. Kaushal GP et al.. 1986. Purification and properties of beta-mannosyltransferase that synthesizes Man-beta-GlcNAc-GlcNAc-pyrophosphoryl-dolichol.. Arch Biochem Biophys 250(1):38-47 PMID: 3021065
- 5. Goto K et al.. 2008. Activity and stability of alpha- and beta-mannosyltransferases in Candida albicans cells cultured at high temperature and at low pH.. Biol Pharm Bull 31(7):1333-6 PMID: 18591770
- 6. Wei D et al.. 2025. [Prokaryotic expression of human Alg1 protein and analysis of the transmembrane domain properties].. Sheng Wu Gong Cheng Xue Bao 41(4):1535-1546 PMID: 40328714
- 7. Revers L et al.. 1999. Development of recombinant, immobilised beta-1,4-mannosyltransferase for use as an efficient tool in the chemoenzymatic synthesis of N-linked oligosaccharides.. Biochim Biophys Acta 1428(1):88-98 PMID: 10366763
- 8. Schwarz M et al.. 2004. Deficiency of GDP-Man:GlcNAc2-PP-dolichol mannosyltransferase causes congenital disorder of glycosylation type Ik.. Am J Hum Genet 74(3):472-81 PMID: 14973778
